Acadia pharmaceuticals announces daybue™ (trofinetide) is now available for the treatment of rett syndrome

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) today announced that daybue™ (trofinetide) is now available for the treatment of rett syndrome in adult and pediatric patients two years of age and older in the united states. daybue has demonstrated the potential to improve the signs and symptoms of rett syndrome. daybue was approved by the u.s.
ACAD Ratings Summary
ACAD Quant Ranking